Definitions and Risk Factors for Drug-Resistant Epilepsy in an Adult Cohort

Alyssa Denton; Lilian Thorpe; Alexandra Carter; Adriana Angarita-Fonseca; Karen Waterhouse; Lizbeth Hernandez Ronquillo

doi:10.3389/fneur.2021.777888

Definitions and Risk Factors for Drug-Resistant Epilepsy in an Adult Cohort

Front Neurol. 2021 Dec 13:12:777888. doi: 10.3389/fneur.2021.777888. eCollection 2021.

Authors

Alyssa Denton¹, Lilian Thorpe², Alexandra Carter^{3

4}, Adriana Angarita-Fonseca^{5

6

7}, Karen Waterhouse⁴, Lizbeth Hernandez Ronquillo^{2

4}

Affiliations

¹ College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
² Community Health and Epidemiology, University of Saskatchewan, Saskatoon, SK, Canada.
³ Division of Neurology, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
⁴ Saskatchewan Epilepsy Program, Department of Medicine, Division of Neurology, University of Saskatchewan, Saskatoon, SK, Canada.
⁵ Universite du Quebec en Abitibi-Temiscamingue, Rouyn Noranda, QC, Canada.
⁶ Centre de Recherche du Centre Hospitalier del l'Universite de Montreal, Montreal, QC, Canada.
⁷ Universidad de Santander, Bucaramanga, Colombia.

Abstract

Background: Less than one-third of people with epilepsy will develop drug-resistant epilepsy (DRE). Establishing the prognosis of each unique epilepsy case is an important part of evaluation and treatment.Most studies on DRE prognosis have been based on a pooled, heterogeneous group, including children, adults, and older adults, in the absence of clear recognition and control of important confounders, such as age group. Furthermore, previous studies were done before the 2010 definition of DRE by the International League Against Epilepsy (ILAE), so data based on the current definitions have not been entirely elucidated. This study aimed to explore the difference between 3 definitions of DRE and clinical predictors of DRE in adults and older adults. Methods: Patients with a new diagnosis of epilepsy ascertained at a Single Seizure Clinic (SSC) in Saskatchewan, Canada were included if they had at least 1 year of follow-up. The first study outcome was the diagnosis of DRE epilepsy at follow-up using the 2010 ILAE definition. This was compared with 2 alternative definitions of DRE by Kwan and Brodie and Camfield and Camfield. Finally, risk factors were analyzed using the ILAE definition. Results: In total, 95 patients with a new diagnosis of epilepsy and a median follow-up of 24 months were included. The median age of patients at the diagnosis of epilepsy was 33 years, and 51% were men. In the cohort, 32% of patients were diagnosed with DRE by the Kwan and Brodie definition, 10% by Camfield and Camfield definition, and 15% by the ILAE definition by the end of follow-up. The only statistically significant risk factor for DRE development was the failure to respond to the first anti-seizure medication (ASM). Conclusion: There were important differences in the percentage of patients diagnosed with DRE when using 3 concurrent definitions. However, the use of the ILAE definition appeared to be the most consistent through an extended follow-up. Finally, failure to respond to the first ASM was the sole significant risk factor for DRE in the cohort after considering the age group.

Keywords: adults; anti-seizure medication; drug-resistant; epilepsy; new-onset; risk factors; uncontrolled seizures.